A61K2800/78

CELL ACTIVATOR OF ANIMAL CELL
20220233547 · 2022-07-28 ·

A cell activator of an animal cell that includes 3H-imidazo[4,5-d][1,2,3]triazine-4,6(5H,7H)-dione.

Method of treating or ameliorating skin conditions with a magnetic dipole stabilized solution

The present invention is directed to methods for treating or ameliorating skin conditions, diabetic conditions, cardiovascular conditions, cancer, infections or metal poisoning, enhancing performance, or providing nutritional support, comprising administering to a subject in need thereof compositions comprising a magnetic dipole stabilized solution (MDSS). The MDSS solution may include additional components and can be provided in a kit.

Personal care compositions comprising fatty acid amide derivatives
11202743 · 2021-12-21 · ·

In one embodiment, the present invention provides a personal care composition, comprising: (i) a compound of Formula (1) at a concentration from 0.0001 wt % to 20 wt % of the composition; ##STR00001## wherein R is selected from the group consisting of C.sub.15-C.sub.23 conjugated dienes, C.sub.15-C.sub.23 hydroxylated mono unsaturated alkenes, and C.sub.15-C.sub.23 hydroxylated alkanes; wherein R1 is selected from the group consisting of H, C.sub.1-C.sub.4 alkyl, —CH.sub.2OH, —CH.sub.2(CH.sub.3)—OH, —[CH.sub.2].sub.4—NH.sub.2, —CH.sub.2—CO.sub.2H, —[CH.sub.2].sub.2—CO.sub.2H, ##STR00002## wherein R3 is —CO.sub.2H; —CH.sub.2CO.sub.2H; —CH.sub.2CH.sub.2CO.sub.2H; and (ii) a cosmetically acceptable carrier.

PROCESS TO PRODUCE KLOTHO PROTEIN IN VITRO
20210388380 · 2021-12-16 ·

A method of producing Klotho protein includes preparing a Klotho plasmid DNA vector, culturing cells, transfecting the cells with the Klotho plasmid DNA vector in a cell culture medium, growing the transfected cells, and harvesting the cell culture supernatant by removing the transfected cells. The Klotho plasmid DNA vector has a mammalian selection marker and a Klotho open reading frame. The cells are primary fibroblast cells and/or mesenchymal stromal cells. A method of manufacturing a cosmetic composition includes combining Klotho protein or the cell culture supernatant with a cosmetically acceptable vehicle. A method of treating a patient to improve the condition and appearance of aging skin includes topically administering the cosmetic composition to the patient. By upregulating the Klotho gene in vitro and incorporating the Klotho protein and growth factors into a composition, transepidermal water loss, skin atrophy, and free radical damage to the skin may be addressed.

Method of identifying a biologically-active composition from a biofilm

The subject invention provides materials and methods that effectively support innate immunity and/or disperse pathogenic biofilms using readily available, nontoxic, natural substances, while supporting restoration of normal microbiotic homeostasis. In one embodiment, the subject invention provides anti-biofilm compositions comprising one or more probiotic organisms, anti-microbial honey, and other ingredients such as prebiotic compounds, other hive products, green tea derivatives, other plant derivatives, and vitamin D3.

GENE EXPRESSION PROMOTER FOR SKIN BEAUTIFICATION

A gene expression promoter for skin beautification contains a fermented extract of aspergillus oryzae as an effective component. The gene expression promotor for skin beautification causes expression of at least one gene for skin beautification among BMP-2, TGFB1, CLDN7, HB-EGF, VEGF-A, LCE3D, and PPAR-D. The fermented extract of aspergillus oryzae is extracted using water after steamed rice as a raw material is fermented with aspergillus oryzae.

Methods for modulating pigmentation by angiotensin-converting enzyme 2 modulation

A cosmetic method for modulating pigmentation in a subject includes administering a modulator of angiotensin-converting enzyme 2 (ACE2 modulator) to the subject. The ACE2 modulator can be an inhibitor of angiotensin-converting enzyme 2 (ACE2 inhibitor), in which case, the ACE2 inhibitor can be administered to increase pigmentation in the subject. The ACE2 modulator can also be an activator of angiotensin-converting enzyme 2 (ACE2 activator), in which case the ACE2 activator can be administered to decrease pigmentation in the subject. The treatment of inflammatory skin disease can also be achieved by inhibition of angiotensin-converting enzyme 2.

AMMONIA OXIDIZING MICROORGANISMS FOR PH MODULATION
20220142911 · 2022-05-12 ·

A method of modulating topical pH of a subject is provided. The methods include administering an effective amount of a preparation comprising ammonia oxidizing microorganisms to the subject. The methods include administering the preparation comprising ammonia oxidizing microorganisms topically to skin of the subject. Related preparations and kits are also provided.

Minoxidil adjuvant therapies
11766392 · 2023-09-26 · ·

Compositions and methods are disclosed herein for inducing (up-regulating) the expression of sulfotransferases in the hair follicles, e.g., the scalp. Increasing sulfotransferase is beneficial for metabolizing pro-drugs that require sulfonation to be activated, e.g., minoxidil sulfate is the active metabolite of minoxidil. A method for combining the compositions described herein with topical minoxidil to enhance minoxidil treatment for androgenetic alopecia is described. Additional methods and compositions include the use of retinoid X receptor agonists, retinoic acid receptor agonists, and nuclear receptor agonists in an RXR−NR heterodimer. Additional methods and compositions include the use of a topical solution containing an alkalinizing agent or an alkalinizing agent used with a penetration enhancer for up-regulating the sulfonating capacity of hair bearing skin, hair follicles, and/or keratinocyte cells. In addition, compositions and methods for increasing or decreasing the growth rate of hair follicles is disclosed by altering the intracellular pH.

Composition for skin whitening or wound treatment, containing liquid plasma

The present invention relates to a composition for skin whitening or wound treatment including liquid-type plasma, and more particularly, to a cosmetic composition for skin whitening and a pharmaceutical composition for treating and preventing skin pigmentation diseases which contain liquid-type plasma as an active ingredient. In addition, the present invention relates to a pharmaceutical composition for wound treatment, a quasi-drug composition, and a health functional food composition, which include liquid-type plasma and a growth factor as active ingredients, and a wound treatment method including a step of administering the composition to a subject or a step of applying the composition on the skin. The composition including liquid-type plasma and a growth factor of the present invention is capable of inducing the proliferation of fibroblasts, thereby exhibiting excellent wound treatment efficacy. Accordingly, the composition including liquid-type plasma and a growth factor of the present invention can be usefully applied to medicines including external preparations for wound treatment, etc.